Glaukos Corporation (NYSE:GKOS) Unveils Investor Presentation in 8-K FilingAliso Viejo, California – Glaukos Corporation, a Delaware-based company specializing in eye care innovations, recently filed an 8-K report with the SEC, disclosing its intent

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Glaukos’s 8K filing here.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.